Icon

HALAVEN (nda201532)- (1MG/2ML (0.5MG/ML))

ERIBULIN MESYLATE EISAI INC
1MG/2ML (0.5MG/ML)
Yes No
2027-Jul-08 2015-Nov-15
2023-Jan-28 None
None No
HALAVEN is a microtubule inhibitor indicated for the treatment of patients with:  Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting.  Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
4 0 3
Total Other Developers 12
Drugs with Suitability No
1MG/2ML (0.5MG/ML) ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 1
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****** *** ***** ****** ******* *********** **** * & **** **, ***** *, ***** *, ************* ******* ******** **** (**** ), *******, *************, ****** ******* ******, ***** (***) ***
****** ******* ******** ****** *************** **., ***. *********** **.*-* ***** ****, ******* **-**** ************* ****** ****, *******, ******* ******, ***** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.